Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
pituitary hormone-release stimulating peptides	2968	57773-63-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: triptorelin arvekap triptoreline tryptorelin triptorelin pamoate triptorelin acetate	A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6. Molecular weight: 1311.47 Formula: C64H82N18O13 CLOGP: -4.59 LIPINSKI: 3 HAC: 31 HDO: 18 TPSA: 487.92 ALOGS: -4.63 ROTB: 33

Molecule

Description

Molfile Inchi Smiles

Synonyms:

triptorelin
arvekap
triptoreline
tryptorelin
triptorelin pamoate
triptorelin acetate

A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.

Molecular weight: 1311.47
Formula: C64H82N18O13
CLOGP: -4.59
LIPINSKI: 3
HAC: 31
HDO: 18
TPSA: 487.92
ALOGS: -4.63
ROTB: 33

Drug dosage:

Dose	Unit	Route
0.13	mg	P
0.10	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	41.70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.67 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.81 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	10 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
June 15, 2000	FDA	ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	2261.38	37.22	354	3212	5508	90619373
Needle issue	464.76	37.22	108	3458	13826	90611055
Ascites	296.72	37.22	99	3467	47641	90577240
Disease progression	284.01	37.22	133	3433	156482	90468399
Syringe issue	250.12	37.22	52	3514	3950	90620931
Product use complaint	192.53	37.22	41	3525	3492	90621389
Abortion spontaneous	142.98	37.22	60	3506	53996	90570885
Off label use	117.86	37.22	177	3389	1102075	89522806
Product administration error	96.39	37.22	37	3529	26386	90598495
Product dose omission issue	91.42	37.22	82	3484	291605	90333276
Progesterone increased	90.63	37.22	12	3554	47	90624834
Ovarian enlargement	75.44	37.22	14	3552	586	90624295
Product physical issue	74.76	37.22	21	3545	5639	90619242
Haemoperitoneum	74.65	37.22	19	3547	3509	90621372
Ovarian haemorrhage	74.00	37.22	13	3553	398	90624483
Incorrect dose administered	68.10	37.22	41	3525	78889	90545992
Product prescribing issue	67.64	37.22	21	3545	7958	90616923
Liquid product physical issue	62.19	37.22	14	3552	1536	90623345
Product administration interrupted	58.40	37.22	21	3545	12471	90612410
Product reconstitution quality issue	51.63	37.22	8	3558	110	90624771
Epiphysiolysis	48.97	37.22	7	3559	53	90624828
Vaginal haemorrhage	48.60	37.22	24	3542	31247	90593634
Epiphyses premature fusion	47.99	37.22	7	3559	62	90624819
Breast enlargement	44.86	37.22	11	3555	1744	90623137
Ectopic pregnancy	42.68	37.22	12	3554	3229	90621652
Product deposit	42.56	37.22	8	3558	359	90624522
Haemoconcentration	42.02	37.22	7	3559	155	90624726
Osteonecrosis of jaw	40.81	37.22	23	3543	39080	90585801
Biochemical pregnancy	40.39	37.22	6	3560	61	90624820
Waist circumference increased	40.34	37.22	9	3557	948	90623933
Growth accelerated	38.79	37.22	5	3561	15	90624866
Product use in unapproved indication	38.29	37.22	56	3510	336180	90288701

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prostatic specific antigen increased	173.02	21.48	67	4794	16858	42599616
Hot flush	151.72	21.48	66	4795	22285	42594189
Needle issue	83.64	21.48	33	4828	8694	42607780
Terminal state	81.04	21.48	27	4834	4396	42612078
Syringe issue	80.76	21.48	32	4829	8524	42607950
Osteonecrosis of jaw	73.05	21.48	38	4823	19011	42597463
Metastases to bone	69.87	21.48	34	4827	14775	42601699
Death	52.53	21.48	144	4717	471041	42145433
Femoral neck fracture	51.40	21.48	19	4842	4190	42612284
Anaemia	43.08	21.48	97	4764	280181	42336293
Inappropriate schedule of product administration	41.76	21.48	53	4808	95849	42520625
Malignant neoplasm progression	38.15	21.48	54	4807	108346	42508128
Respiratory tract infection viral	36.59	21.48	14	4847	3392	42613082
Respiratory tract infection bacterial	36.35	21.48	12	4849	1897	42614577
Ischaemic stroke	34.80	21.48	25	4836	22208	42594266
Product dose omission issue	33.86	21.48	62	4799	154303	42462171
Calculus urinary	33.27	21.48	11	4850	1746	42614728
Meningioma	29.48	21.48	10	4851	1717	42614757
Rhabdomyolysis	29.12	21.48	40	4821	77979	42538495
Erectile dysfunction	27.98	21.48	23	4838	24890	42591584
Hydronephrosis	27.40	21.48	17	4844	11848	42604626
Product prescribing issue	27.35	21.48	14	4847	6759	42609715
Blood testosterone increased	26.46	21.48	9	4852	1558	42614916
Osteoporosis	26.20	21.48	18	4843	14888	42601586
Metastasis	25.84	21.48	12	4849	4693	42611781
Metastases to bladder	25	21.48	5	4856	104	42616370
Pathological fracture	24.49	21.48	12	4849	5281	42611193
Product use complaint	23.36	21.48	9	4852	2222	42614252
Hepatitis fulminant	22.22	21.48	11	4850	4948	42611526
Ureteric rupture	22.16	21.48	3	4858	3	42616471
Haematuria	22.11	21.48	30	4831	57769	42558705
Hormone-refractory prostate cancer	21.91	21.48	7	4854	997	42615477
Asthenia	21.91	21.48	76	4785	280717	42335757

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	1891.07	22.11	322	6726	5038	110577213
Needle issue	354.01	22.11	101	6947	17739	110564512
Syringe issue	180.22	22.11	52	6996	9473	110572778
Prostatic specific antigen increased	174.63	22.11	54	6994	12457	110569794
Ascites	172.46	22.11	94	6954	92714	110489537
Hot flush	111.93	22.11	63	6985	65973	110516278
Osteonecrosis of jaw	107.14	22.11	55	6993	47962	110534289
Product use complaint	91.19	22.11	25	7023	3778	110578473
Progesterone increased	85.46	22.11	12	7036	44	110582207
Metastases to bone	81.94	22.11	40	7008	31332	110550919
Ovarian enlargement	73.94	22.11	14	7034	398	110581853
Ovarian haemorrhage	69.45	22.11	13	7035	347	110581904
Product dose omission issue	66.96	22.11	92	6956	321690	110260561
Product reconstitution quality issue	56.78	22.11	11	7037	354	110581897
Product administration error	56.32	22.11	33	7015	37184	110545067
Product physical issue	54.83	22.11	18	7030	5018	110577233
Malignant neoplasm progression	54.10	22.11	61	6987	174506	110407745
Haemoperitoneum	53.63	22.11	18	7030	5370	110576881
Anaemia	50.50	22.11	109	6939	546977	110035274
Liquid product physical issue	50.14	22.11	13	7035	1587	110580664
Incorrect dose administered	49.99	22.11	46	7002	103595	110478656
Injection site abscess sterile	47.30	22.11	7	7041	40	110582211
Death	45.90	22.11	122	6926	698747	109883504
Product deposit	44.10	22.11	10	7038	695	110581556
Inappropriate schedule of product administration	43.47	22.11	59	6989	203578	110378673
Erectile dysfunction	40.62	22.11	21	7027	18535	110563716
Respiratory tract infection bacterial	40.43	22.11	12	7036	2404	110579847
Femoral neck fracture	38.85	22.11	18	7030	12549	110569702
Ischaemic stroke	38.55	22.11	27	7021	41236	110541015
Epiphysiolysis	38.31	22.11	7	7041	163	110582088
Respiratory tract infection viral	37.08	22.11	14	7034	5864	110576387
Haemoconcentration	36.17	22.11	7	7041	224	110582027
Rhabdomyolysis	33.79	22.11	40	7008	120361	110461890
Congestive cardiomyopathy	30.86	22.11	16	7032	14203	110568048
Pelvic fluid collection	30.47	22.11	8	7040	1025	110581226
Waist circumference increased	30.38	22.11	9	7039	1792	110580459
Metastases to lymph nodes	30.02	22.11	16	7032	15016	110567235
Prostate cancer metastatic	28.41	22.11	11	7037	4932	110577319
Product administration interrupted	28.29	22.11	14	7034	11278	110570973
Product prescribing issue	26.66	22.11	14	7034	12758	110569493
Growth accelerated	26.59	22.11	4	7044	26	110582225
Adnexal torsion	26.28	22.11	6	7042	430	110581821
Neuroendocrine carcinoma metastatic	26.13	22.11	6	7042	441	110581810
Neuroendocrine breast tumour	25.44	22.11	4	7044	36	110582215
Calculus urinary	25.43	22.11	9	7039	3143	110579108
Off label use	25.03	22.11	172	6876	1500013	109082238
Prostate cancer	24.84	22.11	20	7028	37621	110544630
Pulmonary interstitial emphysema syndrome	24.63	22.11	6	7042	569	110581682
Blood testosterone increased	23.62	22.11	7	7041	1395	110580856
Meningioma	23.58	22.11	10	7038	5655	110576596
Hydronephrosis	22.82	22.11	15	7033	20650	110561601
Pituitary apoplexy	22.61	22.11	5	7043	310	110581941
Metastases to bladder	22.19	22.11	5	7043	338	110581913

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02AE04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues
FDA MoA	N0000175654	Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC	N0000175655	Gonadotropin Releasing Hormone Receptor Agonist
MeSH PA	D000080066	Contraceptive Agents, Hormonal
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003271	Contraceptive Agents, Female
MeSH PA	D008186	Luteolytic Agents
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:49323	contraceptive drug
CHEBI has role	CHEBI:63533	gonadotropin releasing hormone agonist
CHEBI has role	CHEBI:64946	anti-HIV agent

Related Drugs by ATC class:

L02AE Gonadotropin releasing hormone analogues 5 drugs

bicalutamide buserelin goserelin histrelin leuprorelin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Advanced Prostatic Carcinoma	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Hypercholesterolemia	contraindication	13644009
Hypertensive disorder	contraindication	38341003	DOID:10763
Spinal cord compression	contraindication	71286001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Smokes tobacco daily	contraindication	449868002
Vertebral Metastases	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Swine	Synchronization of the time of insemination	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
OvuGel	United-AH II LLC	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	11.9	acidic
pKa3	12.81	acidic
pKa4	12.82	acidic
pKa5	13.17	acidic
pKa6	13.43	acidic
pKa7	13.43	acidic
pKa8	13.86	acidic
pKa9	10.75	Basic
pKa10	6.69	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Gonadotropin-releasing hormone receptor	GPCR	P30968	GNRHR_HUMAN	AGONIST	EC50	9.03		WOMBAT-PK	CHEMBL
Gonadotropin-releasing hormone receptor	GPCR		GNRHR_RAT	AGONIST	Ki	8.80		IUPHAR

External reference:

ID	Source
4021400	VUID
N0000148818	NUI
D06247	KEGG_DRUG
124508-66-3	SECONDARY_CAS_RN
4021400	VANDF
4021401	VANDF
C0077275	UMLSCUI
CHEBI:63633	CHEBI
CHEMBL1201334	ChEMBL_ID
CHEMBL1200554	ChEMBL_ID
D017329	MESH_DESCRIPTOR_UI
DB06825	DRUGBANK_ID
1177	IUPHAR_LIGAND_ID
5711	INN_ID
9081Y98W2V	UNII
25074470	PUBCHEM_CID
236538	RXNORM
15638	MMSL
33432	MMSL
d04696	MMSL
004107	NDDF
006246	NDDF
008312	NDDF
008313	NDDF
009526	NDDF
327370004	SNOMEDCT_US
395915003	SNOMEDCT_US
425731006	SNOMEDCT_US
427385009	SNOMEDCT_US
CHEMBL5315073	ChEMBL_ID
140194-24-7	SECONDARY_CAS_RN
9081Y98W2V	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

Try a sample question

triptorelin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: